Summary & Overview
HCPCS J9043: Injection, Cabazitaxel, 1 mg
HCPCS Level II code J9043 designates the injectable oncology drug cabazitaxel, billed per 1 mg. Cabazitaxel is used in systemic chemotherapy regimens and its billing reflects the drug component of infused cancer therapy. Nationally, drug J-codes like J9043 matter for pharmacy and medical benefit coordination, oncology practice revenue, and payer coverage policy for high-cost antineoplastic agents.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage considerations, typical sites of service where cabazitaxel is administered, and operational benchmarks related to drug acquisition and billing units. The publication also summarizes clinical context for cabazitaxel as an infused chemotherapeutic and highlights common billing elements associated with J-code drug claims.
This summary provides actionable reference material for revenue cycle, pharmacy, and oncology practice administrators seeking clarity on code usage, payer engagement, and where to find further policy details. Data not available in the input is noted where specific payer policies or utilization metrics would normally appear.
Billing Code Overview
HCPCS Level II code J9043 represents an injectable chemotherapy agent, cabazitaxel, billed per 1 mg unit. This code denotes the drug supply for intravenous administration of cabazitaxel.
Service Type: Infusion drug administration for oncology treatment.
Typical Site of Service: Hospital outpatient infusion center or physician office infusion suite.
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel presents for second-line systemic chemotherapy with cabazitaxel. The patient arrives to an outpatient oncology infusion center for evaluation by the oncology team, nurse intake, and baseline labs (CBC, CMP) before administration. The oncology advanced practice provider confirms indication, reviews prior chemo tolerance, documents performance status, obtains informed consent, and verifies premedication orders (antiemetic, corticosteroid, antihistamine) and growth factor plan if indicated.
On the day of service the chemotherapy is prepared by pharmacy using J9043 (cabazitaxel, 1 mg) dosed per body surface area and vial concentration. The infusion nurse performs IV access assessment, administers premedications, and initiates cabazitaxel infusion through an infusion pump over the facility’s standard infusion time. The patient is monitored for infusion reactions and cytopenias; vitals are recorded baseline and periodically during the infusion. Post-infusion, the nurse documents drug lot and amount administered, disposes of hazardous waste per policy, and schedules the next cycle. Billing uses J9043 reported per milligram with payer-appropriate units, and modifiers are appended when necessary to indicate circumstances such as billing practitioner, administration location, or specific payment adjustments.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|